ArticleEuropean thyroid journal2026
Association between thyroid hormone and pre-sarcopenic obesity in euthyroid population: a prospective cohort study.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to explore the association between thyroid indicators and pre-sarcopenic obesity, pre-sarcopenia, and visceral obesity in a community-based euthyroid cohort. Methods: A total of 1280 euthyroid residents (42.3% men) aged over 40 years were recruited in 2013-2014 and re-examined in 2015-2016. Thyroid indicators were analyzed. Visceral fat area (VFA) was quantified using magnetic resonance imaging and skeletal muscle mass was calculated by bioelectrical impedance analyzer. Pre-sarcopenic obesity was defined as the coexistence of pre-sarcopenia and visceral obesity. Results: During a mean follow-up of 2.1 years, 127 (14.8%), 156 (21.3%), and 120 (20.1%) participants developed new-onset pre-sarcopenic obesity, pre-sarcopenia, and visceral obesity, respectively. Compared with those with the lowest tertile of baseline serum fT3 levels, participants with the highest tertile had an elevated risk of pre-sarcopenic obesity (risk ratio [RR] 1.82, 95% confidence interval [CI] 1.20-2.76) and pre-sarcopenia (RR 1.49, 95%CI 1.04-2.15). Moreover, per 1 standard deviation increase in serum fT3 levels over 2.1 years was positively associated with incident pre-sarcopenic obesity (RR 1.40, 95%CI 1.28-1.53) and pre-sarcopenia (RR 1.29, 95%CI 1.18-1.40), respectively. Conclusion: Elevated serum fT3 levels were associated with increased risks of pre-sarcopenic obesity and pre-sarcopenia in euthyroid Chinese participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.